Latest / Peptides Weekly / Ep 1: Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were…

Transcript

Ep 1: Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were… · Peptides Weekly

• 0:00
  Phase three results for an investigational, amelin, peptide medicine in diabetes and obesity were released this week. Welcome to the very first episode of Peptides Weekly. Today is September 23rd, 2026. A peptide is a short chain of amino acids. The term now covers approved medicines such as insulin, as well as vial sold online under research use only labels. This show explains what each compound is, how researchers study it, and what the data shows.
• 0:29
  at each level of evidence. Insulin serves as one clear example because it's regulatory
• 0:35
  status, manufacturing record, and clinical observations are documented across peer-reviewed
• 0:41
  sources. The show stays strictly with education and never supplies doses, schedules, combinations,
• 0:47
  sources, or protocols. It never tells anyone to start, stop, or change a treatment. Every
• 0:54
  named compound carries the regulatory status stated in the source material.
• 0:58
  Peptides weekly belongs to the Narra Network, an independent and ad-free set of programs.
• 1:05
  Novel Nordisk reported new Phase III data on an Amelon-based candidate.
• 1:09
  A randomized Phase III trial tested an investigational Amelon peptide candidate
• 1:14
  in adults with obesity or diabetes.
• 1:17
  The company stated the results moved the program closer to potential human use.
• 1:22
  The findings remain at the Phase III randomized human trial level.
• 1:26
  The source for these statements appears in reports linked from x.com.
• 1:31
  Two randomized human trials examined oral semaglutide, a GLP-1 peptide, in patients with
• 1:37
  modeled Alzheimer's disease.
• 1:39
  The trials carried the name evoke.
• 1:42
  Neither trials showed slowing of disease progression.
• 1:45
  The result is a negative finding from phase 3 randomized trials.
• 1:49
  The source for these statements appears in the Lancet.
• 1:52
  An animal study measured neuro-tensin signaling and gut function in a rodent model of type 2 diabetes.
• 1:59
  The measurements focused on altered gastrointestinal function.
• 2:03
  The measurements also focused on neuro-tensin signaling.
• 2:06
  The work used an experimental rodent model.
• 2:09
  The work is at the experimental animal level.
• 2:12
  The source for these statements appears in the peptides journal via sciencedirect.com.
• 2:17
  A rodent study tested an oral ureotensin-2 receptor antagonist in a dietary model of liver disease.
• 2:24
  The compound carried the designation KR36996.
• 2:30
  KR36996 is described as an orally active ureotensin-2 receptor antagonist.
• 2:36
  The study examined attenuation of hepatic inflammation and fibrosis.
• 2:40
  The dietary model used a methionine and coline-deficient diet to induce fibrosync's
• 2:46
  diato hepatitis. The evidence is at the animal study level. Researchers gave
• 2:51
  phoenixin 14 to rodents with chemically induced pancreatitis and recorded
• 2:56
  changes in inflammation and cell death markers. The study recorded changes in
• 3:01
  inflammation markers. The study recorded changes in oxidative stress
• 3:05
  markers. The model used L-arginine to induce acute pancreatitis. The data come from an animal model.
• 3:13
  This week's spotlight centers on insulin, a peptide hormone whose signaling pathway appears
• 3:18
  in many metabolic disease studies. One longitudinal observational study followed 17 Pima Indians whose
• 3:25
  glucose tolerance deteriorated from normal to impaired to diabetic over an average of 5.1 years.
• 3:32
  Transition from normal to impaired glucose tolerance coincided with increased body weight
• 3:37
  and reduced insulin sensitivity.
• 3:40
  Insulin secretion remained relatively preserved until later stages in that human observational
• 3:45
  study.
• 3:47
  Indogin is glucose output rose as tolerance worsened in the same study.
• 3:51
  mitochondrial function was tracked in a separate time course study using Otsuka Long Evans
• 3:56
  Tokushima fatty rats and their non-hyperfagic controls.
• 4:00
  cycles. At five weeks of age, hepatic mitochondrial respiration and enzyme activities were already
• 4:06
  reduced in the obese strain. Insulin resistance and stiotosis developed only at later ages
• 4:11
  in that rodent time course study. Insulin-like growth factor one was measured in a field
• 4:17
  study of 669 wild so-A sheep lambs, sampled at approximately four months of age across
• 4:23
  nine summers. Higher circulating IGF-1 concentrations correlated with faster early growth rates
• 4:30
  and higher over-winter survival in that observational field study of animals. The association held
• 4:37
  after accounting for cohort and environmental variation. Additional observational work examined
• 4:43
  insulin resistance patterns in women with prior miscarriage and in elderly adults stratified
• 4:49
  by obesity status. Post-prandial insulin resistance showed stronger links to miscarriage
• 4:54
  history than fasting measures alone in one multi-center cohort. Sex differences in basal insulin
• 5:01
  secretion emerged more clearly in obese versus non-obese elderly groups. None of these studies
• 5:07
  establish causal mechanisms or test therapeutic interventions. Insulin is an approved biologic medicine.
• 5:13
  The supplied sources do not establish regulatory status or long-term outcome data for any newer
• 5:20
  peptide that match the breadth of human observations accumulated for insulin.
• 5:25
  No source reports oral formulations reaching approval or documents specific manufacturing
• 5:30
  transitions.
• 5:32
  That's peptides weekly.
• 5:34
  This show is education, not medical advice.
• 5:37
  Talk to your own clinician before acting on anything you heard.
• 5:40
  I'm Patrick in Vancouver.
• 5:42
  See you next week.
• 5:42
  week. This episode used AI voice synthesis of my voice. Editorial selection and analysis
• 5:48
  are my own.